secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zentalis Pharmaceuticals, Inc. (ZNTL)
CIK:        0001725160
Form:       8-K
Filed at:   2022-05-31T23:59:59+00:00
Accession:  0001725160-22-000114
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zentalis appoints Cam Gallagher as President, effective May 30, 2022
--------------------------------------------------------------------

- Cam Gallagher, formerly Executive Director and Board member, appointed President, replacing Kimberly Blackwell.
- Initial annual base salary: $560,000; eligible for 50% target bonus.
- Received stock options for 333,218 shares and RSUs for 111,072 shares, vesting over 4 years.
- Gallagher has ties to Recurium IP, which received $10M milestone fees from Zentalis in 2021.
- Employment is at-will; severance includes 12 months salary plus prorated bonus on qualifying termination.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1725160/000172516022000114/0001725160-22-000114-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1725160/000172516022000114/zntl-20220525.htm
  HTML page:      https://secwatch.observer/filing/0001725160-22-000114

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer